{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:43:32Z","timestamp":1790473412110,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The study aims to assess the efficacy and safety of the recently approved S1PR modulator etrasimod in adults with ulcerative colitis during the induction phase through meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systemic search was performed for randomized controlled trials evaluating the efficacy and safety of the S1PR modulator etrasimod using electronic databases PubMed, Embase, the Cochrane Library, Clinical Trials, and the International Clinical Trials Registry Platform. Three studies with 943 patients met the inclusion criteria and were included in this analysis. The study\u2019s primary endpoint was the proportion of patients who achieved clinical remission at week 12. Key secondary endpoints included the proportion of patients with clinical response, endoscopic improvement, and histologic remission. The incidence of adverse effects (AEs), serious AEs (SAEs), and AE-related treatment discontinuation were statistically analyzed to determine the safety of etrasimod.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This study revealed that etrasimod is superior to placebo at the primary endpoint clinical remission (OR = 3.09, 95% CI: 2.04\u20134.69), as well as at the secondary endpoints clinical response (OR = 2.56, 95% CI: 1.91\u20133.43), endoscopic improvement (OR = 2.15, 95% CI: 1.51\u20133.05), and histologic remission (OR = 3.39, 95% CI: 2.03\u20135.68). The proportion of patients with TEAE (OR = 1.34, 95% CI: 1.01\u20131.78) and SAE (OR = 0.77, 95% CI: 0.41\u20131.43) was similar between the etrasimod and placebo groups. Patients receiving etrasimod had slightly higher odds of experiencing headache (OR = 2.07, 95% CI: 1.01\u20134.23), and nausea (OR = 1.84, 95% CI: 0.72\u20134.72). The incidences of upper respiratory tract infection (OR = 0.79, 95% CI: 0.27\u20132.32), nasopharyngitis (OR = 0.40, 95% CI: 0.15\u20131.07), and urinary tract infection (OR = 1.82, 95% CI: 0.59\u20135.60) were generally lower in the etrasimod groups and no treatment-related serious infections were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study demonstrates that etrasimod is effective in treating moderately to severely active ulcerative colitis with a favorable benefit-risk profile at week 12. Etrasimod shows promise as a potential first-line oral therapy for individuals suffering from this disease. Additional RCTs with larger sample sizes and longer observation periods are needed to confirm the sustained efficacy of etrasimod beyond the initial phase.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1420455","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T09:20:58Z","timestamp":1725873658000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"15","author":[{"given":"Jingyue","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiakuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/MOG.0000000000000738","article-title":"Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis","volume":"37","author":"Abraham","year":"2021","journal-title":"Curr. Opin. Gastroenterol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/s2468-1253(21)00065-0","article-title":"Breaking the therapeutic ceiling in drug development in ulcerative colitis","volume":"6","author":"Alsoud","year":"2021","journal-title":"Gastroenterology and hepatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/S0140-6736(23)00228-3","article-title":"The sphingosine-1-phosphate receptor agonist etrasimod in ulcerative colitis","volume":"401","author":"Atreya","year":"2023","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5014","DOI":"10.3390\/jcm12155014","article-title":"Efficacy and safety of S1P1 receptor modulator drugs for patients with moderate-to-severe ulcerative colitis","volume":"12","author":"Bencardino","year":"2023","journal-title":"J. Clin. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.gtc.2020.08.002","article-title":"Biologic therapy for ulcerative colitis","volume":"49","author":"Bhattacharya","year":"2020","journal-title":"Gastroenterology Clin. N. Am."},{"key":"B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev-immunol-020711-075011","article-title":"Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs","volume":"30","author":"Cyster","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/nejmoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/1744666x.2022.2069562","article-title":"Emerging therapies for ulcerative colitis","volume":"18","author":"Hanzel","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/9781119536604.ch8","article-title":"Assessing risk of bias in a randomized trial","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1111\/bph.12678","article-title":"Lysophospholipid receptor nomenclature review: IUPHAR Review 8","volume":"171","author":"Kihara","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40264-021-01057-z","article-title":"Safety of S1P modulators in patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"44","author":"Lasa","year":"2021","journal-title":"Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Gastroenterology and hepatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/cpdd.1379","article-title":"Safety, pharmacokinetics, and pharmacodynamics of etrasimod: single and multiple ascending dose studies in healthy adults","volume":"13","author":"Lee","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/s2468-1253(21)00432-5","article-title":"Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities","volume":"7","author":"Ma","year":"2022","journal-title":"Gastroenterology and hepatology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41575-023-00793-0","article-title":"Etrasimod for ulcerative colitis: evaluating phase III results","volume":"20","author":"Matsuoka","year":"2023","journal-title":"Nat. Rev. Gastroenterology and Hepatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","volume":"16","author":"Peyrin-Biroulet","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohn's Colitis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme","volume":"50","author":"Sandborn","year":"2019","journal-title":"Alimentary Pharmacol. and Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/nejmoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e00128","DOI":"10.14309\/ctg.0000000000000128","article-title":"Treatment pathways leading to biologic therapies for ulcerative colitis and crohn's disease in the United States","volume":"11","author":"Siegel","year":"2020","journal-title":"Clin. Transl. gastroenterology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin. gastroenterology hepatology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1093\/ecco-jcc\/jjad100","article-title":"Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and meta-analysis","volume":"17","author":"Solitano","year":"2023","journal-title":"J. Crohn's Colitis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00011-023-01829-6","article-title":"Sphingosine 1-phosphate (S1P) receptor modulators as an induction and maintenance therapy for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials","volume":"73","author":"Suilik","year":"2023","journal-title":"Inflamm. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/bs.apcsb.2019.11.003","article-title":"Sphingolipids as mediators of inflammation and novel therapeutic target in inflammatory bowel disease","volume":"120","author":"Sukocheva","year":"2020","journal-title":"Adv. protein Chem. Struct. Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/dmd.120.000220","article-title":"Absorption, metabolism, and excretion, in vitro pharmacology, and clinical pharmacokinetics of ozanimod, a novel sphingosine 1-phosphate receptor modulator","volume":"49","author":"Surapaneni","year":"2021","journal-title":"Drug metabolism Dispos. Biol. fate Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1007\/s12325-020-01473-0","article-title":"Single-dose pharmacokinetics of ozanimod and its major active metabolites alone and in combination with gemfibrozil, itraconazole, or rifampin in healthy subjects: a randomized, parallel-group, open-label study","volume":"37","author":"Tran","year":"2020","journal-title":"Adv. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.dld.2016.01.011","article-title":"Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - multicenter European cohort study","volume":"48","author":"Van Assche","year":"2016","journal-title":"Dig. liver Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J. Crohn's Colitis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"i619","DOI":"10.1093\/ecco-jcc\/jjac190.0620","article-title":"P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials","volume":"17","author":"Vermeire","year":"2023","journal-title":"J. Crohn's Colitis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/imt-2022-0255","article-title":"Etrasimod for the treatment of ulcerative colitis","volume":"15","author":"Wils","year":"2023","journal-title":"Immunotherapy"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1420455\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T09:21:02Z","timestamp":1725873662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1420455\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":34,"alternative-id":["10.3389\/fphar.2024.1420455"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1420455","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"article-number":"1420455"}}